Abstract
During the past few years, a major focus of leukemia research has centered on tyrosine kinases as potential therapeutic targets. This is due in large part to the success of imatinib mesylate (STI571, Gleevec), which has proven effective as a therapy for chronic myeloid leukemias bearing the t(9;22) encoding the BCR-ABL kinase. It has become increasingly evident that mutations producing constitutively active tyrosine kinases play a role in leukemogenesis. Another kinase that has drawn significant attention is the FMS-like tyrosine kinase 3 (FLT3). FLT3 is expressed in most childhood acute leukemias. Select genetic subgroups possess particularly high-level expression, with a significant percentage therein harboring activating mutations. In this review we will discuss FLT3 as a potential therapeutic target in childhood acute leukemias. We will highlight the role of FLT3 in hematopoiesis, and how when activated, it may play a role in the development of acute myeloid or acute lymphoblastic leukemia. We will examine the successes in elucidating FLT3 function in acute leukemias, highlight current FLT3 targeted therapeutics, and discuss how FLT3 inhibitors might be used in combination therapies in the future.
Keywords: BCR-ABL kinase, hematopoietic stem cells, Internal Tandem Duplication, STAT-5, CEP-701, leukemia stem cells
Current Drug Targets
Title: FLT3 as a Therapeutic Target in Childhood Acute Leukemia
Volume: 8 Issue: 6
Author(s): Matthew C. Stubbs and Scott A. Armstrong
Affiliation:
Keywords: BCR-ABL kinase, hematopoietic stem cells, Internal Tandem Duplication, STAT-5, CEP-701, leukemia stem cells
Abstract: During the past few years, a major focus of leukemia research has centered on tyrosine kinases as potential therapeutic targets. This is due in large part to the success of imatinib mesylate (STI571, Gleevec), which has proven effective as a therapy for chronic myeloid leukemias bearing the t(9;22) encoding the BCR-ABL kinase. It has become increasingly evident that mutations producing constitutively active tyrosine kinases play a role in leukemogenesis. Another kinase that has drawn significant attention is the FMS-like tyrosine kinase 3 (FLT3). FLT3 is expressed in most childhood acute leukemias. Select genetic subgroups possess particularly high-level expression, with a significant percentage therein harboring activating mutations. In this review we will discuss FLT3 as a potential therapeutic target in childhood acute leukemias. We will highlight the role of FLT3 in hematopoiesis, and how when activated, it may play a role in the development of acute myeloid or acute lymphoblastic leukemia. We will examine the successes in elucidating FLT3 function in acute leukemias, highlight current FLT3 targeted therapeutics, and discuss how FLT3 inhibitors might be used in combination therapies in the future.
Export Options
About this article
Cite this article as:
Stubbs C. Matthew and Armstrong A. Scott, FLT3 as a Therapeutic Target in Childhood Acute Leukemia, Current Drug Targets 2007; 8 (6) . https://dx.doi.org/10.2174/138945007780830782
DOI https://dx.doi.org/10.2174/138945007780830782 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain
Current Drug Targets Potential Application of 5-Aryl-Substituted 2-Aminobenzamide Type of HDAC1/2- Selective Inhibitors to Pharmaceuticals
Current Pharmaceutical Design High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Liposome-Nanogel Structures for Future Pharmaceutical Applications: An Updated Review
Current Pharmaceutical Design C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Integrated Genomic and Pharmacological Approaches to Identify Synthetic Lethal Genes as Cancer Therapeutic Targets
Current Molecular Medicine Allelic Variations in 5, 10-Methylenetetrahydrofolate Reductase Gene and Susceptibility to Cervical Cancer in Indian Women
Drug Metabolism Letters Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Mismatches with Mutated Transcribing Genes at Leukemogenic S-Phase Binding/Start Sites – Potential Targets for Therapy with Enzyme Inhibitors
Current Stem Cell Research & Therapy Lipid Nucleoside Conjugates for the Treatment of Cancer
Current Pharmaceutical Design Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Utilization of Analytical Omics Tools in the Molecular Diagnostics of Multiple Myeloma
Current Molecular Medicine Immunotherapy of Kidney Cancer
Current Clinical Pharmacology “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design